Opt 6.02(1)(c) (c) Decrease in vision.

Opt 6.02(1)(d) (d) Pale or red swelling of the periocular or periorbital tissues.

Opt 6.02(1)(e) (e) Nausea.

Opt 6.02(1)(f) (f) Vomiting.

Opt 6.02(1)(g) (g) Fainting.

Opt 6.02(1)(h) (h) Mental confusion.

Opt 6.02(1)(i) (i) Cessation of respiration.

Opt 6.02(1e) (1e) “Approved institution” means an institution approved by the board and accredited by a regional or professional accrediting organization which is recognized by the Council for Higher Education Accreditation or its successor or the federal department of education, in accordance with ss. 449.17 (1m) (b) and 449.18 (2) (a) 2., Stats.

Opt 6.02(1n) (1n) “Classroom hour” means a minimum of 50 minutes of lecture, group discussion, or laboratory. “Classroom hour” does not include time spent working in a clinic other than as part of a laboratory directly associated with a course in pharmacology.

Opt 6.02(1s) (1s) “Course of study in pharmacology” means a course of study completed in an approved institution after 1973 in general and clinical pharmacology as it relates to optometry with the characteristics described in s. 449.17 (1m) (b), Stats. For a course, such as a continuing education course, that does not lead to a degree in optometry to qualify as part of a course of study in pharmacology, the course must include at least one examination on course content.

Opt 6.02(3) (3) “DPA” or “diagnostic pharmaceutical agent” means an agent authorized under s. SPS 10.02.

Opt 6.02(6) (6) “TPA” or “therapeutic pharmaceutical agent” means an agent authorized under s. SPS 10.03.

Opt 6.02 History History: Cr. Register, December, 1990, No. 420, eff. 1-1-91; r. (3), Register, September, 1997, No. 501, eff. 10-1-97: CR 05-036: cr. (intro.) and (3) Register January 2006 No. 601, eff. 2-1-06; CR 06-116: renum. (1) to be (1m), cr. (1), r. (2) and (5), r. and recr. (3) and am. (6), Register May 2007 No. 617, eff. 6-1-07; correction in (1), (1m), (3), (6) made under s. 13.92 (4) (b) 7., Stats., Register November 2011 No. 671; CR 19-027: renum. (1) to (1) (intro.) and am., cr. (1) (a) to (i), r. (1m), cr. (1e), (1n), (1s), am. (3), r. (4), am. (6) Register January 2020 No. 769, eff. 2-1-20; correction in (1) (intro.) made under s. 35.17, Stats., Register January 2020 No. 769.

Opt 6.025 Opt 6.025 Adverse drug reaction referral plan.

Opt 6.025(1) (1) An optometrist who wants to use diagnostic pharmaceutical agents authorized under s. SPS 10.02 or therapeutic pharmaceutical agents authorized under s. SPS 10.03 shall submit an adverse drug reaction referral plan prior to providing pharmaceutical agents. The plan shall be submitted to the department on an approved form in which the optometrist agrees to do all of the following:

Opt 6.025(1)(a) (a) Refer any patient who notifies the optometrist of an adverse drug reaction to appropriate medical specialists or facilities.

Opt 6.025(1)(b) (b) Routinely advise all patients to immediately contact the optometrist if the patient experiences adverse reactions.

Opt 6.025(1)(c) (c) Place in a patient’s permanent record information describing any adverse drug reactions experienced by the patient and the date and time that any referral was made.

Opt 6.025(2) (2) The plan shall include the names of at least 3 physicians, physician clinics, or hospitals to whom the optometrist agrees to refer patients who experience an adverse drug reaction. At least one of these physicians shall be skilled in the diagnosis and treatment of diseases of the eye.

Opt 6.025(3) (3) An optometrist authorized to use diagnostic or therapeutic pharmaceutical agents shall file a revised adverse drug reaction referral plan with the department within 10 working days after the optometrist designates a new physician, physician clinic, or hospital to which the optometrist agrees to refer patients who experience adverse drug reactions.

Opt 6.025(4) (4) An optometrist authorized to use therapeutic pharmaceutical agents shall file with the department within 10 working days of its occurrence a report on any adverse drug reaction resulting from the optometrist’s administration of the agents. This report shall include all of the following:

Opt 6.025(4)(a) (a) The optometrist’s name, address, and license number.

Opt 6.025(4)(b) (b) The patient’s name, address, and age.

Opt 6.025(4)(c) (c) The patient’s presenting problem, the diagnosis, the agent administered and the method of administration, the reaction, and the subsequent action taken.

Opt 6.025 Note Note: The TPA Adverse Reaction Report (Form #1728) and DPA/TPA Certification Application are available on the department’s website at dsps.wi.gov, or by request from the Department of Safety and Professional Services, P.O. Box 8935, Madison, Wisconsin 53708, or call [phone].

Opt 6.025 History History: CR 19-027: cr. Register January 2020 No. 769, eff. 2-1-20.

Opt 6.03 Opt 6.03 Certificate to use diagnostic pharmaceutical agents.

Opt 6.03(1) (1) A licensed optometrist who has submitted an adverse drug reaction referral plan in accordance with s. Opt 6.025 is authorized to use diagnostic pharmaceutical agents if any of the following applies:

Opt 6.03(1)(a) (a) The board initially issued a license to practice optometry to the optometrist on or after August 1, 2006.